Previous Next

2024-03-19

Efficacy and safety of enfortumab and pembrolizumab in urothelial carcinoma

Oncology

Until now, no treatment has shown superior efficacy to platinum-based chemotherapy in improving overall survival in patients with treatment-naive locally advanced or metastatic urothelial carcinoma. In this phase 3 clinical trial, investigators compared the efficacy and safety of enfortumab and pembrolizumab to platinum-based chemotherapy in 886 patients with previously untreated locally advanced or metastatic urothelial carcinoma. Progression-free survival and overall survival were longer in the enfortumab - pembrolizumab arm than in the chemotherapy arm. The median number of treatment cycles was 12 in the enfortumab - pembrolizumab arm, and 6 in the chemotherapy arm. 

Source(s) :
Thomas Powles et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024 Mar 7;390(10):875-888. ;

Last press reviews


Eat without fear: anti-ige antibody omalizumab, a new weapon against food allergies

#Omalizumab #FoodAllergies #IgE #Anaphylaxis #Immunotherapy  ...

Vitamin D and tuberculosis: an overestimated protection?

By Ana Espino | Published on July 18, 2025 | 2 min read

Outdoor temperature and severe hyponatremia: a growing threat in the age of climate change

By Lila Rouland | Published on July 17, 2025 | 3 min read  ...